These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36548336)

  • 1. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.
    Choupani E; Madjd Z; Saraygord-Afshari N; Kiani J; Hosseini A
    PLoS One; 2022; 17(12):e0279522. PubMed ID: 36548336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
    Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
    PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
    Chica-Parrado MR; Kim GM; Uemoto Y; Napolitano F; Lin CC; Ye D; Bikorimana E; Fang Y; Lee KM; Mendiratta S; Hanker AB; Arteaga CL
    Cancer Lett; 2024 Nov; 604():217219. PubMed ID: 39244005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
    Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
    Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
    Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
    Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
    Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
    Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
    [No Abstract]   [Full Text] [Related]  

  • 7. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
    Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
    Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceritinib is a novel triple negative breast cancer therapeutic agent.
    Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
    Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
    Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
    Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
    Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
    Wu Y; Xue J; Li J
    Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
    Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
    Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
    Chen F; Zhang Z; Yu Y; Liu Q; Pu F
    Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.